Epinephrine

ARS Pharma recently announced that the FDA will likely rule on a new drug application for the company’s neffy epinephrine nasal spray — designed to treat type 1 allergic reactions such as anaphylaxis — by Oct. 2.

ARS Pharma has submitted a response letter to the FDA as it seeks approval for its neffy epinephrine nasal spray, which is designed to treat type I allergic reactions such as anaphylaxis, according to a company press release.

WASHINGTON — Most physicians believed that needle-free epinephrine delivery would be preferable among patients, and that it would lead to more patients carrying it and using it faster, survey results showed.

WASHINGTON — A nurse-led intervention improved pediatric food allergy knowledge, although it also revealed “concerning” shortcomings in certain areas of identification and management, research showed.

WASHINGTON — Four pooled studies noted similar pharmacodynamic performance for epinephrine delivered via nasal spray or autoinjector, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

WASHINGTON — Epinephrine formulated as nasal powder demonstrated superior stability compared with autoinjector epinephrine, according to an abstract presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

WASHINGTON — An epinephrine nasal spray resulted in outcomes that were comparable with injections in pediatric patients, according to a poster presented at the American Academy of Allergy, Asthma & Immunology Annual Meeting.

Most people who reported a reaction to a COVID-19 vaccine said they were unlikely to receive another vaccine in the future, according to a survey from Massachusetts General Hospital.

ARS Pharma continues to study the effectiveness and safety of its neffy epinephrine nasal spray as patients with allergies wait for an alternative to autoinjectors for anaphylaxis treatment.